Back to Newsroom

Corbus Pharmaceuticals Holdings, Inc. Prices Underwritten Public Offering of Common Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced the pricing of a $32.5 million underwritten public offering of 4,650,000 shares of its common stock at a public offering price of $7.00 per share. Corbus has also granted the underwriters a 30-day option to purchase up to an additional 697,500 shares of common stock on the same terms as the underwriters are purchasing the base number of shares.
READ MORE…